Opthea is a biopharmaceutical company focused on developing innovative therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD). Their lead investigational drug candidate, sozinibercept (OPT-302), represents a novel approach in the treatment landscape, functioning as a first-in-class VEGF-C and VEGF-D 'trap.' This mechanism of action aims to inhibit the angiogenesis and vascular permeability driven by these factors, which are known to contribute to the progression of wet AMD. By targeting the VEGF-C and VEGF-D pathways, Opthea seeks to enhance the efficacy of existing anti-VEGF-A therapies, addressing the significant unmet medical needs of patients who do not respond adequately to current treatments.

The company is actively conducting pivotal Phase 3 clinical trials (COAST and SHORe) to evaluate the effectiveness of sozinibercept in combination with standard anti-VEGF-A therapies. These trials aim to demonstrate improved visual outcomes and overall efficacy compared to monotherapy. Opthea's commitment to scientific innovation is underscored by its strong intellectual property portfolio, which includes patents for OPT-302 and related technologies, further solidifying its position in the competitive landscape of retinal disease treatment. The FDA has recognized the potential of sozinibercept by granting it Fast Track designation, highlighting the urgency and importance of addressing the challenges faced by patients with wet AMD.

Australia

Opthea Limited (ASX:OPT) is a public biotechnology company listed on the ASX and based in Melbourne, Australia.

Opthea is developing OPT-302, a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Eye Diseases

Opthea

Eye disease

Wet age-related macular degeneration

<p class="font_7">OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).</p>

Opthea

Company Details